**All Interactions with Atazanavir/cobicistat (Evotaz)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Atazanavir/cobicistat** | **Effect on Drug Levels** | **Effect on Atazanavir/cobicistat Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Daclatasvir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=329&post=4#727)  (Daklinza) | - | - | - | - | - | Inhibition of CYP3A4 | Decrease daclatasvir dose to 30 mg daily |
| Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=329&post=4#727)  (Viekira) | - | - | - | - | - | - | Do not coadminister |
| Elbasvir/grazoprevir  (Zepatier) | Elbasvir 50 mg QD with grazoprevir 100 mg QD | 300 mg/100 mg daily or 300 mg/150 mg daily | elbasvir AUC ↑ 4.8 fold grazoprevir AUC ↑ 10.6 fold | ATV AUC ↑ 43% by grazoprevir | May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition | OATP1B1/3 inhibition by atazanavir | Contraindicated: Do not coadminister |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |